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EPI Update for Friday, October 9, 2009 
Center for Acute Disease Epidemiology (CADE) 
Iowa Department of Public Health (IDPH) 
Items for this week’s EPI Update include:  
 Guidance for use of live nasal spray H1N1 vaccine in vaccination clinics 
 Updated: pediatric antiviral dosing syringe and compounding 
information for 2009 H1N1 and seasonal flu 
 UHL requesting laboratories submit one rapid test positive for 
confirmation per week and note change in “Influenza Algorithm,” 
effective Oct. 12, 2009  
 Information on rapid influenza testing 
 Influenza activity is steadily increasing  
Guidance for use of live nasal spray H1N1 vaccine in vaccination clinics 
Guidance for Use of Live Nasal Spray H1N1 Vaccine in Public Health and Private 
Vaccination Clinics When Vaccine Supplies Are Limited 
  
Those in the highest priority group who are recommended to get the live nasal spray 
H1N1 vaccine: 
 Healthy persons who live with or provide care for infants less than 6 months 
of age,  and who are between 2 through 49 years of age 
 Healthy health care workers giving direct patient care and are less than 50 
years of age (except those who work with severely immune-compromised 
patients such as on hospital bone marrow transplant units).  Almost all Iowa 
health care workers can receive the LAIV vaccine 
 Healthy children 2 years of age through 4 years of age 
  
Those in the highest priority group who should wait until inactivated injection is 
available: 
 Pregnant women 
 Persons living with or providing care to infants less than 6 months of age,  
and who are 1) over 6 months of age up to 2 years of age, or 2) older than 50 
years of age, or 3) have chronic medical conditions 
 Health care workers giving direct patient care and who  1) have chronic 
medical conditions, or 2) are 50 years of age or older,  or 3) provide care for 
severely immune-compromised patients such as on hospital bone marrow 
transplant units 
 Healthy children 6 months of age up to 2 years of age 
 Children between 6 months and 18 years of age and have chronic medical 
conditions 
  
Updated: pediatric antiviral dosing syringe and compounding information  
 Pharmacists and physicians who care for pediatric patients should be aware of two 
issues: (1) the possible need to compound Tamiflu® locally if commercially 
manufactured pediatric oral suspension is not available, and (2) the need to ensure that 
the units of measure on the suspension dosing dispenser and the dosing instructions 
match.  
  
Compounding an oral suspension from Tamiflu® 75mg capsules is possible when 
commercially manufactured oral suspension is not readily available. See FDA-approved 
instructions at 
www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM147992.pdf 
  on pages 18 and 19.  
There is also a need to ensure that the units of measure on the dosing dispenser and the 
dosing instructions match, i.e. ensure the units of measure on the dosing instructions 
match the dosing device provided. For more information, see the updated interim 
recommendations issued by CDC on September 22, 2009 for the use of antivirals in the 
treatment and prevention of influenza which can be found at 
www.cdc.gov/H1N1flu/recommendations.htm   and in the 2009-2010 Influenza Season: 
Information for Pharmacists available at 
www.cdc.gov/H1N1flu/pharmacist/pharmacist_info.htm 
UHL requesting laboratories submit only one rapid test positive for confirmation 
per week  
Since UHL implemented the Influenza Algorithm, on 8/1/2009, there has been new 
guidance from CDC and ASM indicating the poor performance of the rapid tests with 
Novel H1N1 virus (note change in algorithm).  Effective Oct 12, 2009, laboratories may 
submit one rapid test positive for confirmation per week to UHL. Note: all hospitalized 
patients with respiratory illness regardless of rapid test performance or result. See 
algorithm at: www.uhl.uiowa.edu/kitsquotesforms/influenzaalgorithm.pdf  
  
Information on rapid influenza testing 
CDC states that most patients with influenza like illness do not require diagnostic 
influenza testing for clinical management. Rapid influenza diagnostic tests (RIDTs) are 
widely available but have variable sensitivity
 
(range 10 – 70 percent) for detecting 2009 
H1N1 influenza; compared to rRT-PCR test (done at UHL). More information on 
sensitivity, specificity and interpretation of RIDT results can be found at: 
 www.cdc.gov/h1n1flu/guidance/rapid_testing.htm 
  
ASM notes:  'negative results do not rule out influenza especially when clinical signs 
and symptoms are consistent with influenza-like illness,' and 'positive results may need 
confirmation especially when prevalence of influenza in the population is low.'”  
www.asm.org/images/pdf/Policy/fluasmalgorithm10-05-09.pdf 
   
Keep in mind that the test result does not impact patient care; at this time only 2009 
H1N1 has been detected in Iowa. In the next few days, the live nasal spray vaccines will 
be given and this vaccine can give a false positive rapid test result.  
  
Influenza activity is steadily increasing.  
Influenza activity is steadily increasing in Iowa; school absences of over 10 percent of the 
student body have been reported from every region of Iowa. Hospitalizations are also 
increasing, with the patient’s average age being 20. For surveillance information refer to 
www.idph.state.ia.us/adper/iisn.asp.   
  
Meeting announcements and training opportunities 
None 
  
Have a healthy and happy week and flu free week! 
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